Related by context. All words. (Click for frequent words.) 86 Endovascular Valve Edge 79 EVEREST II 71 Phase III AFFIRM 71 BRIM3 70 multicenter prospective 70 Oral Fingolimod 70 number NCT# ClinicalTrials.gov 69 Intervention Effectiveness 69 BOLDER II 69 CYT# potent vascular disrupting 69 CARE HF 69 Carotid Revascularization Endarterectomy vs. 69 Aggressive Reduction 69 Clinical Antipsychotic Trials 69 Prospective Randomized 68 multicenter randomized controlled 68 undergoing elective percutaneous 68 randomized multicenter trial 68 Pooled Analysis 68 RECORD1 68 CALGB # [002] 68 SORT OUT III 68 ExTRACT TIMI 68 Cholesterol Levels SPARCL 67 registrational Phase 67 Randomized Double blind 67 Acute Decompensated Heart Failure 67 SPIRIT FIRST 67 AIR2 Trial 67 CUSTOM II 67 TAXUS ATLAS 67 Relapsing Multiple Sclerosis 67 BR.# 67 Acute Myocardial Infarction 67 Acute Ischemic Stroke 67 BRIM2 67 Multicenter 67 SPIRIT IV 67 recurrent malignant glioma 67 Carotid Stenting 67 randomized controlled multicenter 66 Safinamide 66 Left Ventricular Dysfunction 66 SPIRIT III 66 Randomized Phase 66 PERSEUS 66 phase IIb study 66 prospective multicenter 66 Combination REOLYSIN R 66 randomized blinded 66 Intervention Effectiveness CATIE 66 CAMMS# 66 randomized Phase IIb 66 Refractory Angina 66 prospective multicentre 66 EURIDIS 66 Digital Mammographic Imaging 66 RE LY 66 Randomized Controlled 66 Randomized Double Blind Placebo 66 relapsing remitting MS RRMS 66 Val HeFT 66 Sipuleucel T 66 placebo controlled clinical 66 Pivotal Phase III 66 Pivotal Trial 66 relapsing multiple sclerosis 66 evaluating tivozanib 66 landmark ATHENA 66 CAPRIE 66 Myocardial Infarction Study 66 Multicenter Randomized Double 66 relapsed MM 66 multicenter multinational 65 Randomised 65 Randomized Double Blind 65 Long Term Efficacy 65 Cardiac Resynchronization 65 Study Evaluating 65 Prospective Multicenter 65 multicenter placebo controlled 65 Systemic Sclerosis 65 HORIZONS AMI trial 65 HORIZONS AMI 65 First Patient Enrolled 65 double blinded randomized 65 LHRH receptor positive 65 CaPSURE 65 opioid naive 65 PLX STROKE targeting 65 Subgroup Analysis 65 Hormone Refractory Prostate Cancer 65 Randomized Evaluation 65 rALLy clinical trial 65 Randomized Phase II 65 CATIE AD 65 Observational Study 65 Clinical Trial Results 65 Phase III multicenter 65 Controlled Trial 65 Platelet Inhibition 65 Preclinical Study 65 BCIRG 65 Meta Analysis 65 ACTEMRA TM 65 prospective randomized placebo 65 Double Blind Placebo 65 Thrombolysis 65 HYVET 65 Phase 1a clinical 65 blinded randomized placebo controlled 65 Heterozygous Familial Hypercholesterolemia 65 Meets Primary Endpoint 64 multicenter 64 Patient Outcomes 64 STRIDE PD 64 Maven Semantic 64 Randomized Study 64 multicentre randomized 64 prospective nonrandomized 64 MERLIN TIMI 64 By JENNIFER LEARN 64 prospective observational 64 CALGB 64 phase IIb clinical 64 Percutaneous Coronary Intervention 64 AA Amyloidosis 64 recurrent glioblastoma multiforme 64 stage IIIb IV 64 Clinical Outcome 64 USpella 64 pharmacokinetic PK 64 MADIT II 64 II Clinical Trial 64 ORACLE MS 64 Phase 2b Clinical Trial 64 TMC# C# 64 placebo controlled dose escalation 64 fosbretabulin 64 Diabetic Foot Ulcer 64 randomized Phase III 64 IMPACT DCM 64 ENDEAVOR IV 64 prospective longitudinal 64 riociguat 64 randomized multicenter 64 ASTEROID 64 CLARITY TIMI 64 ABSORB clinical 64 Phase Ib clinical 64 RE LY trial 64 ECASS 64 TAXUS ARRIVE 64 #th Annual Interscience 64 CIMZIA TM certolizumab pegol 64 Newly Diagnosed Multiple Myeloma 64 ABSORB trial 64 Patients Treated With 64 multicenter phase 64 Endarterectomy 64 Presents Positive 64 Gynecologic Oncology Group 64 Hepatocellular Carcinoma HCC 64 phase IIa 64 Glucosamine Chondroitin Arthritis 64 AVERROES 64 Severe Sepsis 64 Prostate AdenoCarcinoma Treatment 64 Risk Stratification 64 Heart Failure Patients 64 Teriflunomide 64 NSABP B 64 GOUT 64 placebo controlled Phase III 64 trials RCTs 64 TO AVOID PREGNANCY WHILE 64 AVOREN 64 Long Lesion 64 oral FTY# 64 Brentuximab Vedotin SGN 64 TAXUS IV 64 Sustained Efficacy 63 Cancer Incidence Mortality 63 HCV SPRINT 63 Screening Trial 63 Chronic Heart Failure 63 Controlled Study 63 HIV HCV coinfected 63 EDEMA3 trial 63 Pharmacokinetic 63 prospective randomized multicenter 63 Therapeutics TCT scientific 63 Randomized controlled 63 Aneurysm Repair 63 zoledronic acid Reclast 63 Phase III placebo controlled 63 evaluating mipomersen 63 Cardiotoxicity 63 multicenter Phase III 63 Tolvaptan 63 RE LY ® 63 Phase #/#a 63 Renal Artery 63 recurrent metastatic ovarian cancer 63 Prednisone Against Refractory 63 Surgical Treatment 63 DASISION 63 HCV NS5B polymerase 63 Group RTOG 63 sirolimus eluting stents 63 STENT 63 Screening Trial DMIST 63 Multicenter Automatic Defibrillator Implantation 63 multicentre prospective 63 AVN# Phase 63 phase IIIb 63 Unstable Angina 63 multicenter Phase 63 Randomized Controlled Trials 63 Evaluation WISE 63 PROactive study 63 CINQUIL 63 Prolongs Survival 63 Hsp# Inhibitor 63 REALITY Trial 63 Patency 63 Thromboembolism 63 ASSERT 63 orally inhaled migraine 63 refractory chronic lymphocytic 63 Deforolimus 63 Stent Thrombosis 63 Vascugel ® 63 paclitaxel poliglumex 63 EXPLORE Xa 63 #rd Annual CTRC 63 multicenter randomized placebo controlled 63 ENESTnd 63 PERSEUS clinical program 63 TAXUS VI 63 retrospectively analyzed 63 Patients Undergoing 63 ongoing Phase 1b 63 ID NCT# 63 Demonstrates Positive 63 nonrandomized 63 VADT 63 TRANSFORMS 63 IMPROVE HF 63 Naive Patients 63 Initiates Phase II 63 Phase 2b Study 63 RRMS patients 63 nucleoside naive 63 Placebo Controlled Trial 63 galiximab 63 comparing XIENCE V 63 multicenter Phase II 63 EchoCRT 63 ST Segment Elevation 63 Phase IIIb 63 Relapsed Multiple Myeloma 63 BARI 2D 63 treatment naive genotype 63 hyperphenylalaninemia HPA due 63 minimally symptomatic 63 Chronic Myeloid Leukemia 63 evaluating REVLIMID 62 CHAMPION PCI 62 Complications Trial 62 THAT ARE DIFFICULT TO 62 Venous Thromboembolism 62 oral rivaroxaban 62 Completes Enrollment 62 PRoFESS 62 Completes Patient Enrollment 62 CHARISMA trial 62 Glatiramer Acetate 62 Demonstrates Efficacy 62 CUSTOM III 62 Pivotal Phase 62 NEVO RES 62 ACRIN 62 PROactive Study 62 multicenter randomized 62 Pivotal Clinical Trial 62 dual endothelin receptor antagonist 62 Demonstrates Sustained 62 FOLOTYN ® 62 longitudinal cohort study 62 prospective randomized controlled 62 NCIC CTG 62 paclitaxel eluting stents 62 Postmenopausal Women 62 ADVANCE ILLUMINATE 62 Randomized Clinical Trial 62 Malignant Glioma 62 Atypical Hemolytic Uremic Syndrome 62 Severe Asthma 62 phase Ib 62 prospective multicenter study 62 morphometric vertebral fractures 62 Preclinical Efficacy 62 MEND CABG 62 CTAP# Capsules 62 Initiate Phase 62 International Verapamil SR 62 Bayer HealthCare Onyx Pharmaceuticals 62 dose escalation phase 62 psoriatic arthritis PsA 62 treatment naïve genotype 62 bazedoxifene conjugated estrogens 62 Bucindolol 62 Intervention Trial GAIT 62 novel VDA molecule 62 Randomized Controlled Trial 62 Prostate Lung Colorectal 62 CYPHER R stent 62 Nesiritide 62 J Am Coll 62 EDEMA3 62 Investigational Treatment 62 Multicenter Phase 62 complement inhibitor eculizumab 62 Coronary Revascularization 62 abstracts summarizing 62 CURRENT OASIS 7 62 AACR IASLC Joint 62 ACUITY trial 62 confirmatory clinical 62 Initiates Phase III 62 underwent resection 62 Phase 1b clinical trials 62 Phase III Trial 62 #:#-#,# CrossRef Medline [002] 62 recurrent metastatic 62 Raloxifene STAR 62 assessing T DM1 62 Acute Stroke 62 Recurrent Glioblastoma 62 LUX Lung 62 multicentre randomized controlled 62 Tumor Response 62 Non inferiority 62 Clinical Outcomes Utilizing Revascularization 62 PRIMO CABG2 62 Hormone Receptor Positive 62 Metastatic Melanoma 62 SIMPADICO 62 Metastatic Prostate Cancer 62 patientswith 62 Phase Ib IIa 62 Wisconsin Sleep Cohort 62 Initiated Phase 62 Tanespimycin 62 retrospective cohort 62 Myocardial Infarction 62 Septic Shock 62 WEB OF SCIENCE 62 HuMax EGFr 62 demonstrated antitumor activity 62 Renal Cell Carcinoma 62 Clinical Evaluation 62 TEMSO 62 Clinical Efficacy 62 Left Ventricular 62 Randomized Phase III 62 Placebo controlled 62 recurrent glioma 62 Echocardiographic 62 Improves Outcomes 62 Shows Promise Against 62 Phase III randomized 62 heFH 62 ASCO Breast Cancer 62 Carotid Endarterectomy 62 Prospective Randomized Trial 62 Complicated Skin 62 Placebo Controlled 62 deep venous thromboses 61 Coronary Artery Bypass Graft 61 histologically confirmed 61 Eluting Stent 61 antiretroviral naïve 61 Dual Antiplatelet Therapy 61 Patients Receiving 61 Hepatocellular Carcinoma 61 STICH trial 61 Arch Surg 61 Phase IIb Trial 61 LUMINATE 61 catheter occlusion 61 Phase III Pivotal 61 Trial Evaluating 61 AVADO 61 CORD II 61 Alpha Tocopherol Beta Carotene 61 NATRECOR ® 61 Sapacitabine 61 Xelox 61 NO# [002] 61 Phase III Clinical Trial 61 Vidaza ® 61 Romidepsin 61 Multicentre 61 PICSO ® 61 phase IIb trial 61 RNAi Therapeutic 61 subanalysis 61 Novel Oral 61 Asthma Intervention 61 prospective multicenter randomized 61 randomized controlled clinical 61 R lenalidomide 61 FFR measurements 61 Denufosol 61 substudy 61 HCV RESPOND 2 61 Breaking Clinical Trials 61 deCODE AF TM 61 invasive candidiasis 61 AIR CF2 61 Neovascular AMD 61 cisplatin gemcitabine 61 Phase Ib II 61 CRLX# 61 Intracoronary 61 phase IIa clinical 61 Prostate Cancer Prevention 61 Phase 2b Trial 61 mg administered orally 61 Juvenile Idiopathic Arthritis 61 Accelerated Partial Breast Irradiation 61 relapsed myeloma 61 Randomized Trials 61 Outcome Sciences 61 Angiographic 61 HDL Selective Delipidation 61 Paroxysmal Nocturnal Hemoglobinuria PNH 61 Neoadjuvant 61 Chronic Hepatitis C 61 teriflunomide 61 ENDEAVOR III 61 Overactive Bladder 61 Outpatient Setting 61 double blinded placebo 61 everolimus eluting stents 61 Mg Usa 61 #:#-#,# CrossRef Medline [001] 61 alvespimycin 61 retinal vein occlusion induced 61 Patient Registry 61 Pharmacokinetics PK 61 Treatment Outcome 61 trial evaluating PRX# 61 Spine Patient Outcomes 61 CCX# B 61 Evidence Therapeutic 61 Stenting Trial CREST 61 Acute Liver Failure 61 weekly subcutaneous injections 61 worsening thrombocytopenia 61 Vascugel 61 Hypertrophy 61 stent DES 61 ENDEAVOR II 61 Stent Restenosis 61 Oral Calcitonin 61 Intervention Trial 61 randomized clinical 61 Systolic Hypertension 61 kidney urologic 61 placebo controlled Phase 61 Pegylated Liposomal Doxorubicin 61 Adjuvant Chemotherapy 61 Am J Geriatr 61 ACCORD Eye 61 See CLINICAL PHARMACOLOGY 61 bone marrow reticulin deposition 61 ORAL Solo 61 transcatheter aortic valve implantation 61 Advanced Melanoma 61 Alemtuzumab 61 Decompensated Heart Failure 61 medically inoperable 61 Practice Patterns 61 Desvenlafaxine Succinate 61 ONTARGET 61 unstable angina UA 61 keloid scarring 61 Subgroup analysis 61 AVAiL 61 PROTECT AF 61 familial amyloidotic polyneuropathy FAP 61 TIMI Study Group 61 Coronary Angiography 61 Multicenter Randomized 61 chronic thromboembolic pulmonary 61 Diabetic Macular Edema 61 Nymox NX 61 EmbraceAC 61 smoldering multiple myeloma 61 Systematic Review 61 ST Elevation Myocardial 61 ThermoDox ® clinical 61 Myelofibrosis 61 nonmetastatic 61 CYPHER R Sirolimus eluting 61 Hepatotoxicity 61 intravesical infusion therapy 61 Catheter Ablation 61 XIENCE V PROMUS Stent 61 AIR CF1 61 INSPIRE Trial Phase III 61 Granted Orphan Drug 61 Raloxifene Evaluation MORE 61 undergoing coronary angiography 61 Treatment Naive Patients 61 somatostatin analog 61 candesartan cilexetil 61 Ophena TM 61 Hemodialysis Patients 61 descending thoracic 61 Dialysis Outcomes 61 Diabetes Interventions 61 briakinumab 61 prospectively stratified 61 multicentre 61 BARACLUDE R 61 Late Breaker 61 ICON7 61 comparing alemtuzumab 61 Vaccine Immunology 61 Preclinical Data 61 NICE SUGAR 61 Hodgkin lymphoma HL 61 ZYBRESTAT fosbretabulin 61 drug eluting stent implantation 61 chronic myeloid 61 Infarct 61 neoadjuvant treatment 61 multicenter randomized double 60 Catheterization 60 GAMMAGARD 60 Castration Resistant Prostate Cancer 60 unresectable tumors 60 Histological 60 receptor tyrosine kinase inhibitor 60 ORAL Sync 60 Gastric Cancer 60 REVIVE Diabetes 60 RIO Lipids 60 AML MDS 60 Meta analyzes 60 Matrix Phase 2b 60 Topline Results 60 ACTIVE W 60 Daclizumab 60 STRATEGY FOR AN OPEN 60 Stereotactic Body Radiation Therapy 60 crizotinib PF # 60 Etanercept 60 Suicidality 60 Active Ulcerative Colitis 60 patients undergoing percutaneous 60 Services #:#-#,# Abstract 60 MAGE A3 ASCI 60 Cardiovascular Outcomes 60 prospectively defined 60 Proc Am Soc 60 occlusion CRVO 60 Knee Osteoarthritis 60 PFO migraine 60 osteoporotic compression fractures 60 CLARITY study 60 refractory acute myeloid 60 Intracranial Aneurysms 60 Restenosis 60 Recurrent Breast Cancer 60 MEK Inhibitor 60 VICTOR E3 60 AACR San Antonio 60 Ischemic Stroke 60 Dose Ranging 60 Ischemic 60 Heart Failure Trial 60 Ozarelix 60 paroxysmal nocturnal hemoglobinuria 60 DAPT Study 60 Delcath Phase III 60 DAPT 60 Antiviral Therapy 60 Trandolapril 60 Soft Tissue Sarcoma 60 Dose Escalation 60 Ambulatory Blood Pressure 60 Ventricular Arrhythmias 60 Acute Coronary Syndromes 60 Infarction 60 Aggressive Drug Evaluation 60 APPRAISE 60 Treat Parkinson Disease 60 glucocorticoid induced osteoporosis 60 JAK2 Inhibitor 60 HCV Protease Inhibitor 60 INTEGRILIN R 60 APEX PD 60 elacytarabine 60 carotid artery stenting 60 undergone radical prostatectomy 60 MGd 60 LHON 60 viral kinetic 60 HER2 Positive Breast Cancer 60 receiving VELCADE 60 Neuroendocrine Tumors 60 venous thromboembolic disease 60 phase IIb 60 DU #b 60 Antitumor Activity 60 ROCKET AF 60 Initiates Clinical Trial 60 FIX HF 5 60 HeFH 60 Synta Announces 60 Reduces Mortality 60 recurrent GBM 60 Phase 2a clinical 60 blinded placebo controlled 60 oral antidiabetic medication 60 Phase III VISTA 60 asymptomatic metastatic 60 Breast Cancer Recurrence 60 multicentric 60 FOLFOX6 chemotherapy regimen 60 Coronary CTA 60 TG MV 60 placebo controlled multicenter 60 KRN# 60 Pafuramidine 60 Adult Stem Cell Therapy 60 colorectal liver metastases 60 Degarelix 60 PRIMO CABG 60 PreCISe 60 Plaque Psoriasis 60 Presents Preclinical 60 Safety Tolerability 60 Myelodysplastic Syndromes 60 candidate CRLX# 60 multicenter randomized clinical 60 PROSTVAC TM 60 ILLUSTRATE 60 Telik logo TELINTRA 60 COU AA 60 antiretroviral naive 60 SYNTAX trial 60 Cardiac Resynchronization Therapy 60 Sangamo BioSciences Announces 60 Vulnerable Plaque 60 stage IIIB 60 Non Alcoholic Steatohepatitis 60 homozygous familial hypercholesterolemia 60 Endometrial Cancer 60 ACCOMPLISH 60 ADVEXIN therapy 60 Monotherapy 60 Golimumab 60 papillary renal cell carcinoma 60 Osteoporotic Fractures 60 Patients Treated 60 J Am Acad 60 Subarachnoid hemorrhage 60 novel orally inhaled 60 ug dose 60 Pyridorin 60 basal bolus regimen 60 visilizumab 60 haematologic 60 atypical Hemolytic Uremic Syndrome 60 non valvular atrial 60 Successfully Completes Phase 60 Improves Survival 60 refractory colorectal cancer 60 reduce serum phosphate 60 Advaxis Phase 60 Fondaparinux 60 Chronic HCV 60 Cervical Dysplasia 60 Phase III ADT 60 trastuzumab emtansine T DM1 60 ASCO GU 60 eosinophilic asthma 60 http:/www.clinicaltrials.gov 60 silent ischemia 60 Zemplar Capsules 60 Arch Neurol 60 Hypertensive Patients 60 Antiviral Activity 60 CT Angiography 60 Fractional Flow Reserve 60 Clinical Outcomes 60 Preclinical Models 60 Entereg R 60 carotid artery stenting CAS 60 Phase III HEAT 60 V Everolimus Eluting Coronary 60 WHEL 60 HeFT 60 Ovarian PLCO Cancer 60 Primary Hypercholesterolemia 60 Relapsing Remitting Multiple Sclerosis 60 relapsed ALL 60 leukemia AML 60 Active Rheumatoid Arthritis 60 Cell Lymphoma 60 Decitabine 60 pharmacokinetic PK study 60 NSABP 60 Phase #b/#a clinical 60 CYPHER R Sirolimus Eluting 60 Phase III psoriasis 60 Occlusive Disease 60 forodesine 60 Multivessel Evaluation 60 dirucotide MBP# 60 cisplatin resistant 60 Therapeutic Efficacy 60 Overactive Bladder OAB 60 unstable angina pectoris 60 SABCS 60 aripiprazole Abilify 60 vaccinated PNH patients 60 paclitaxel cisplatin 60 Pharmacokinetic Pharmacodynamic 60 TRA 2P 60 Refractory Hodgkin Lymphoma 60 systemic anaplastic large 60 Phase IIa Clinical Trial 60 Localized Prostate Cancer 59 de novo kidney transplant 59 Onyx Pharmaceuticals Announces 59 abacavir Ziagen 59 Vicinium TM 59 REVIVE TA 59 Myelodysplastic Syndrome MDS 59 ZOLINZA 59 preclinical efficacy 59 Aortic Stenosis 59 EMPOWER ™ 59 Diabetic Neuropathy 59 HF ACTION 59 hypercholesterolemic patients 59 metastatic HRPC 59 Phase IIIb clinical 59 Afatinib 59 ANN INTERN MED 59 Rigel R# 59 Remission Maintenance 59 VELCADE melphalan 59 Radiation Therapy Oncology 59 Acute Heart Failure 59 Cerebril TM 59 Multicenter Study 59 Aflibercept 59 Telik Announces 59 Motesanib 59 carotid endarterectomy CEA 59 Sirolimus eluting 59 Omacetaxine 59 transcranial Doppler ultrasound 59 RCW Breast Cancer 59 Systemic Delivery 59 Intravesical 59 Carotid 59 Curaxin CBLC# 59 Placebo Controlled Study 59 TMS Therapy 59 PEGylated interferon beta 1a 59 BARACLUDE ® 59 Initiate Phase III 59 BoNTA 59 Thoraxcenter Erasmus University 59 NOMID 59 Medullary Thyroid Cancer 59 myelodysplastic myeloproliferative diseases 59 metastatic malignant 59 Alimentary Tract 59 stage IIIb 59 evaluating Nexavar 59 Tyrima 59 Shows Efficacy 59 Warfarin Coumadin 59 gefitinib Iressa 59 Advanced Renal Cell 59 Vildagliptin 59 Ragweed Allergy 59 Cardiac Allograft Rejection 59 Pulmonary Arterial Hypertension 59 CYP#A# CYP#D# 59 transthyretin TTR mediated amyloidosis 59 Blind Placebo Controlled 59 Phase IIb III 59 Metastatic Renal Cell Carcinoma 59 naïve HCV 59 multicenter study 59 Sorafenib HCC Assessment 59 Novel Mechanism 59 Immunomedics Announces 59 ACCORD Lipid 59 Multiple Ascending Dose 59 Adjunctive Therapy 59 antithrombotic therapy 59 acute PAO 59 branch RVO 59 neratinib 59 undergoing Percutaneous Coronary 59 Radiofrequency Ablation 59 clevidipine 59 Inflammatory Markers 59 Trial NLST 59 Left Ventricular Hypertrophy 59 Cardiac Biomarkers 59 unique alkylating agent 59 HGS ETR2 59 cancer mCRC 59 Tyrosine Kinase Inhibitor 59 Rheumatoid Arthritis Patients 59 Treatment Shows Promise 59 Stent Implantation 59 Peginterferon 59 Malignant Melanoma 59 Adjunctive 59 Pharmacokinetic Study 59 dose escalation clinical 59 Elagolix 59 ASCO GI 59 Group ECOG 59 gadolinium enhanced 59 Treating Chronic 59 alfa 2a 59 Myelodysplastic Syndrome 59 Women Ischemia Syndrome 59 Acute Myocardial 59 Primary endpoints 59 Cardiol 59 prospectively enrolled 59 GetGoal Phase III 59 Achieves Primary Endpoint 59 zotarolimus eluting stent 59 ClinicalTrials.gov 59 Dupuytren Disease 59 Catheter Associated 59 Cutaneous T 59 Arch Intern Med 59 Idiopathic Pulmonary Fibrosis 59 EOquin TM phase 59 randomized Phase 2b 59 Therapeutic Targets 59 TAXUS V 59 OLYMPIA registry 59 Clinicaltrials.gov 59 XIENCE TM 59 PROMUS R 59 intravenous belinostat 59 RLAI 59 Carcinoid 59 Demonstrates Significant 59 everolimus eluting 59 pralatrexate injection folate analogue 59 Srdan Verstovsek 59 Study Shows Promise 59 Slows Progression 59 Invasive Breast Cancer 59 Antihypertensive 59 MYTHOS trial 59 Slow Progression 59 TAXUS TM 59 Oncolytic Reovirus 59 rALLy 59 America HFSA 59 colesevelam HCl 59 Hematological 59 cell carcinoma RCC 59 CYP#D# genotype 59 Aortic Dissection 59 relapsed refractory multiple myeloma 59 Patient Enrollment 59 MADIT 59 azilsartan medoxomil 59 oral ridaforolimus 59 Prostate Cancer Patients 59 anti arrhythmic drug 59 PCI ExTRACT TIMI 59 Diabetic Macular Edema DME 59 Metastatic Colorectal Cancer 59 TAXUS Express Stent 59 SPARCL 59 pain palliation 59 Investigational Compound 59 conducted retrospective cohort 59 either acutely decompensated 59 Transcatheter 59 RAVEL 59 Sentinel Lymph Node Biopsy 59 Zoraxel 59 Trial ASCOT 59 Aliskiren 59 Cimzia TM 59 #mg BID [001] 59 Comorbidities 59 alfuzosin 59 signal detection CTSD 59 ZACTIMA 59 Sirolimus eluting Coronary Stent 59 Investigational Drug 59 Antiplatelet Therapy 59 Cannabinor 59 observational cohort 59 Initiates Enrollment 59 observational cohort study 59 evaluating satraplatin plus 59 symptomatic carotid stenosis 59 Advanced Heart Failure 59 Campath alemtuzumab 59 dosing cohorts 59 J Clin 59 Rare Genetic 59 #-# Full Text 59 Phase 1b Clinical Trial 59 Diabetes ACCORD 59 immunomodulatory agents 59 medically refractory 59 Solid Tumors 59 XIENCE V demonstrated 59 pharmacogenomic translational research 59 Survival Benefit 59 ToGA 59 Cloretazine 59 Quinamed 59 Pirfenidone 59 NCT# ClinicalTrials.gov 59 evaluating Vectibix 59 -#.# log# copies mL 59 ARCOXIA 59 Clinical Trial Data 59 MEND CABG II 59 Ambrisentan 59 XIENCE V Everolimus Eluting 59 Enzastaurin 59 chronic myocardial ischemia 59 NCT# 59 coinfected patients 59 Renal Impairment 59 Nicotine Vaccine 59 pulmonary metastasis 59 Randomized Placebo controlled 59 ADMIRE HF 59 Venous Thrombosis 59 IMPACT IMmunotherapy 59 Adjuvant Therapy 59 Node Positive 59 evaluating Prochymal 59 Phase IIb Clinical Trial 59 Tiotropium 59 Cardiovascular Risk 59 Alzheimer Disease Cooperative 59 acute promyelocytic leukemia APL 59 lintuzumab SGN 59 PARTNER Trial 59 randomized discontinuation trial 59 visceral metastases 59 Multi Ethnic Study 59 icatibant 59 Cardiac Function 59 Functional Outcomes 59 ziprasidone Geodon 59 endometriosis ovarian cysts 59 fluvastatin 59 Diabetic Nephropathy 59 proliferative retinopathy 59 Postmenopausal 59 Eluting 59 active comparator 59 evaluating T DM1 59 TRANSDUR ® 59 demonstrated clinically meaningful 59 ELADUR ™ 59 Critical Limb Ischemia CLI 59 allogeneic hematopoietic stem cell 59 CONQUER OB 59 steroid refractory 59 Phase 1b clinical 59 ALN VSP Phase 59 HIV coinfected 59 Chronic Bronchitis 59 Sleep Disturbances 59 RTOG 59 IMPDH inhibitor